Stankovic Srdjan R.
Known title: PresidentCIK: 0001432545
Associated companies
Transaction History
| ACAD | ▼ Sell | Open Market | 1,847 | $28K | 11/21/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,250 | — | 11/19/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,969 | — | 10/15/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,326 | $21K | 10/15/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,865 | $52K | 5/2/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 9,616 | — | 4/29/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,501 | $36K | 2/23/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 4,919 | $0 | 2/23/2022 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 5,444 | — | 1/6/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,937 | $45K | 1/6/2022 | View on chart |
| ACAD | ▼ Sell | Open Market | 2,803 | $53K | 11/22/2021 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 6,250 | — | 11/19/2021 | View on chart |
| ACAD | ▼ Sell | Open Market | 1,338 | $23K | 10/18/2021 | View on chart |
| ACAD | ▲ Buy | Option Exercise | 2,969 | — | 10/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates
RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.
RBC Lowers ACAD Target to $36 Amid Patent and Phase 2 Updates. RBC Capital maintained an Outperform rating on Acadia Pharmaceuticals but lowered its price target to $36. This move comes as the company reports progress on patents and Phase 2 trials. Recent articles also suggest the stock may be trading below its estimated fair value, highlighting a contrast between current market pricing and fundamental developments.